The Promise of Preventive Cancer Vaccines by Lollini, Pier Luigi et al.
 Vaccines 2015, 3, 467-489; doi:10.3390/vaccines3020467 
 
vaccines 
ISSN 2076-393X 
www.mdpi.com/journal/vaccines 
Review 
The Promise of Preventive Cancer Vaccines 
Pier-Luigi Lollini 1,†,*, Federica Cavallo 2,†, Patrizia Nanni 1 and Elena Quaglino 2 
1 Department of Experimental Diagnostic and Specialty Medicine (DIMES), University of Bologna, 
Viale Filopanti 22, Bologna 40126, Italy; E-Mail: patrizia.nannni@unibo.it 
2 Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, 
University of Torino, Via Nizza 52, Torino 10126, Italy; E-Mails: federica.cavallo@unito.it (F.C.); 
elena.quaglino@unito.it (E.Q.)  
† These authors contributed equally to this work. 
* Author to whom correspondence should be addressed; E-Mail: pierluigi.lollini@unibo.it;  
Tel.: +39-051-209-4786; Fax: +39-051-242-169. 
Academic Editor: Mary Lenora (Nora) Disis 
Received: 17 April 2015 / Accepted: 8 June 2015 / Published: 17 June 2015 
 
Abstract: Years of unsuccessful attempts at fighting established tumors with vaccines have 
taught us all that they are only able to truly impact patient survival when used in a preventive 
setting, as would normally be the case for traditional vaccines against infectious diseases. 
While true primary cancer prevention is still but a long-term goal, secondary and tertiary 
prevention are already in the clinic and providing encouraging results. A combination of 
immunopreventive cancer strategies and recently approved checkpoint inhibitors is a further 
promise of forthcoming successful cancer disease control, but prevention will require a 
considerable reduction of currently reported toxicities. These considerations summed with 
the increased understanding of tumor antigens allow space for an optimistic view of the future. 
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1. Cancer Prevention: A Primer 
Prevention aims at reducing cancer morbidity and mortality [1]; attempts are made to cover cancer at 
every step throughout its progression from normal cells to metastatic spread. Prevention is conventionally 
subdivided into primary, secondary and tertiary (Tables 1 and 2). 
Table 1. Standard definitions of prevention. 
Type of 
prevention 
Institute of Medicine of the National Academies, USA [2] IARC, World Health Organization [3] 
Primary 
Primary prevention refers to health promotion, which 
fosters wellness in general and thus reduces the likelihood 
of disease, disability, and premature death in a nonspecific 
manner, as well as specific protection against the inception 
of disease. 
Primary prevention is prevention of disease by reducing 
exposure of individuals to risk factors or by increasing 
their resistance to them. 
Secondary 
Secondary prevention refers to the detection and 
management of presymptomatic disease, and the prevention 
of its progression to symptomatic disease. 
Secondary prevention (applied during the preclinical 
phase) is the early detection and treatment of disease. 
Screening activities are an important component of 
secondary prevention. 
Tertiary 
Tertiary prevention refers to the treatment of symptomatic 
disease in an effort to prevent its progression to disability or 
premature death. The overlap with treatment is self-evident, 
and perhaps suggests that preventive medicine has grandiose 
territorial ambitions. Be that as it may, there is a legitimate 
focus on prevention even after disease develops, such as the 
prevention of early cancer from metastasizing […] 
Tertiary prevention (appropriate in the clinical phase) is 
the use of treatment and rehabilitation programmes to 
improve the outcome of illness among affected 
individuals. 
Table 2. Types of cancer prevention. 
Cancer 
prevention 
Aim Target Non-immunological examples Immunological examples 
Primary 
Removal or 
avoidance of 
cancer risk 
factors 
Healthy 
individuals 
Healthy diet;  
Ban on carcinogens in the workplace;  
Quitting smoking;  
Tamoxifen in healthy women;  
Prophylactic mastectomy in 
hereditary breast cancer 
Anti- HBV and HPV vaccines 
Secondary 
Early diagnosis 
and therapy 
Pre-symptomatic 
cancer bearers 
Pap test;  
Mammography;  
Colonoscopy 
Anti- Her2 and MUC1 vaccines 
against preneoplastic or early 
neoplastic lesions 
Tertiary 
Prevention of 
relapse and 
metastasis 
Survivors with 
occult neoplastic 
lesions 
Prophylactic radiotherapy;  
Adjuvant chemotherapy 
Adjuvant monoclonal antibodies;  
Adjuvant therapeutic vaccines;  
Intravesical instillations of Bacillus 
Calmette-Guerin 
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1.1. Primary Cancer Prevention 
The aim of primary prevention is the removal of risk factors from the lives of healthy individuals to, 
therefore, avoid cancer development altogether. This concept derives from studies of exogenous 
carcinogens, including occupational carcinogens and tobacco smoke [4]. Then came the idea that 
exposure to endogenous carcinogens could also be prevented using specific drugs (chemoprevention), 
such as selective estrogen receptor modulators and aromatase inhibitors, which reduce the exposure of 
the mammary epithelium to estrogens [5], and non-steroidal anti-inflammatory drugs, which dampen 
carcinogenic inflammation in the colonic mucosa [6,7].  
Vaccines against carcinogenic viruses have provided a novel twist to the tale of primary cancer 
prevention (Table 2). The first successful example of this was the vaccine against the hepatitis B virus 
(HBV), which can cause chronic hepatitis, cirrhosis, and liver cancer. Pioneering studies on Taiwanese 
children gave a 70% reduction in hepatocellular carcinoma after the vaccination program [8]. Soon to 
follow were vaccines against the human papilloma virus (HPV), which is essentially a family of 
carcinogenic, sexually transmitted viruses that cause a spectrum of neoplastic diseases, ranging from 
benign lesions to metastatic carcinomas. Pre-approval trials showed very high vaccine efficacy, with a 
level of cancer prevention of up to 100% [9]. The widespread adoption of vaccination programs could 
lead, for the first time in human history, to the disappearance of a lethal carcinoma, just as vaccination 
led to the eradication of smallpox.  
1.2. Secondary Cancer Prevention  
Secondary cancer prevention is formed around the concept of cancer progression. Symptomatic, 
malignant tumors not only result from the dimensional growth of smaller lesions, but also from the 
progressive accumulation of multiple genetic alterations that drive a normal cell to change into a 
metastatic tumor. Hence, early diagnosis can uncover neoplastic lesions that are smaller and, more 
importantly, less advanced and more easily cured than those that are diagnosed after the onset of 
symptoms. Secondary prevention is implemented at the population level by means of mass screenings, 
such as Pap tests, mammography scans, and colonoscopy procedures [4]. Early diagnosis in itself is 
obviously useless without effective early therapy. Thus, to be more precise, secondary cancer prevention 
consists of early diagnosis followed by early therapy. In most instances, it is surgery that is used to 
definitively treat early neoplastic lesions discovered in early diagnosis. Where this is the case, 
immunoprevention is not expected to play a role. However, there is a wide range of conditions that fall 
on the boundary line between high-risk preneoplasia and early neoplasia, for which surgery might not 
be the treatment of choice and which are currently often left untreated, or are only treated with low 
efficiency chemopreventive agents [10]. There is currently a lack of highly effective approaches to the 
prevention of progression in oral leukoplakia, asbestosis, and monoclonal gammopathies, to name only 
a few. These and many others are potential candidates for the development of vaccines and other types 
of immunological secondary prevention. 
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1.3. Tertiary Cancer Prevention  
Tertiary cancer prevention is actual therapy that aims to avoid tumor recurrence and metastatic 
dissemination. Two typical examples are prophylactic radiation treatments for breast cancer patients, to 
reduce the risk of local recurrence after lumpectomy [11], and adjuvant drug therapy for patients at risk of 
distant micrometastases after the removal of a primary tumor with unfavorable prognostic parameters [12]. 
As commented by Katz and Ali (see Table 1) [2], “The overlap (of tertiary prevention) with treatment is 
self-evident, and perhaps suggests that preventive medicine has grandiose territorial ambitions. Be that 
as it may, there is a legitimate focus on prevention even after disease develops, such as the prevention 
of early cancer from metastasizing…”. A conceptual difference between adjuvant therapy and the 
therapy of metastatic patients is that the former is administered on a probabilistic basis (i.e., variable 
proportions of subjects with and without the disease receive the same treatments), whereas the latter is 
administered deterministically (i.e., only affected patients are treated). The probabilistic element, which 
is a fundamental property of prevention, is the reason why preventive medicine labels adjuvant therapies 
as tertiary prevention.  
Going beyond the theoretical issue, we found that a vaccine designed for cancer immunoprevention 
was ineffectual against established tumors, but prevented the growth of micrometastases [13], and we 
argued that the conceptual framework of preventive medicine could be appropriate to define the 
therapeutic limits of cancer vaccines [14]. 
A major problem in the development of preventive cancer vaccines is the direct translation from 
preclinical studies to large primary prevention trials in humans. We argued that a more feasible way 
would go from successful primary cancer prevention in mice to tertiary prevention (i.e., adjuvant therapy) 
in humans, and only then to primary or secondary prevention in humans [14]. For this reason, in the 
present review, we discuss both immunopreventive and (selected) immunotherapeutic approaches.  
2. Toward Cancer Immunoprevention: Lessons Learned from Preclinical Testing 
The use of vaccines in the prevention of infection-associated tumors is a natural and direct consequence 
of the general principles of vaccination and has grown to become a cancer prevention reality [15–17]. The 
reasons why vaccination can be applied to non-infectious tumors, which make up the majority of human 
cancers, are perhaps less intuitive. The characterization of several tumor antigens in non-infection-related 
cancers [7], evidence for the fact that immune responses against these antigens are detectable in a 
substantial proportion of patients, and an improved understanding of the relationship between tumors 
and the immune system [18,19] have all provided the rationale behind and have led to the development 
of many sophisticated strategies for anti-tumor vaccination [20].  
There are three broad types of cancer vaccines: cell-, protein/peptide-, and gene-based vaccines 
(Figure 1), and none of them are devoid of pitfalls. Cell-based vaccines can be prepared with autologous 
or allogeneic tumor cells [21], or most often with autologous dendritic cells (DC) pulsed or transfected 
with tumor antigens in various forms (i.e., tumor lysates, purified proteins or peptides, DNA or RNA) [22]. 
However, immunogenic, cell-based vaccines have features that hamper their cost-effective, large-scale 
production as exemplified by sipuleucel-T odyssey (which is further examined in Section 3.3). Being 
molecularly defined synthetic vaccines, protein/peptide- and gene-based vaccines are more suitable for 
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large-scale pharmaceutical manufacturing processes. However, the former display a limited immunogenicity, 
thus requiring the use of adjuvants. In the case of peptides, a further limitation is represented by the fact 
that their application is limited to patients with specific human leukocyte antigen (HLA) molecules [23]. 
The major drawback of gene-based vaccines is their limited uptake and consequent limited antigen 
transcription by transfected cells [24]. Their administration through electroporation or viral-mediated 
delivery solves the issue but opens new problems. In the case of electroporation, the availability of 
clinically approved devices and patients’ compliance have limited, until now, their use in clinic [25].  
In the case of viral-mediated delivery, the problems are mainly related to potential dangers associated 
with the administration of live virus together with the presence of anti-viral neutralizing antibodies in 
patients [26].  
 
Figure 1. Schematic representation of the different anti-cancer vaccination strategies.  
The three broad types of cancer vaccines used are shown. Cell-based vaccines include cancer 
cells or, most often, DC pulsed or transfected with various sources of tumor antigens as 
depicted in the inset. 
Harnessing the patient’s own adaptive immunity to fight cancer cells without harming normal cells 
is, in principle, a powerful weapon with which to combat any type of cancer. Indeed, anti-tumor 
vaccination has a long history of success in immunization-protection experiments, and several types of 
anti-cancer vaccines have been successfully designed, manufactured, and pre-clinically tested [27]. 
However, effectiveness in inducing a measurable immune response and in extending patients’ overall 
survival has been modest in clinical trials. Only very recently have promising results from a handful of 
clinical trials modified the cancer vaccination landscape [20], which is now entering a new era [28].  
The discrepancy between the efficacy of vaccines in preclinical experiments and clinical trials is 
actually deceptive, as a careful analysis of preclinical data would have predicted clinical failure in most 
Vaccines 2015, 3 472 
 
 
cases. In retrospect, we now know that the experimental results that have led to the enthusiastic clinical 
application of many anti-cancer vaccines showed bias, since most of these experiments were performed 
by injecting transplantable cancer cell lines into young and healthy syngeneic mice that did not present 
the cancer-induced constraints on immune response and the central and peripheral mechanisms of tumor 
antigen tolerance [29–31]. Moreover, the high proliferation rate of transplantable tumor cells does not 
reproduce the architectural and cellular complexity of real cancers and thus minimizes the consequences 
of tumor genetic instability, immune editing, and tumor escape ability [32–34]. 
2.1. Genetically Modified Mouse Models  
The advent of genetically modified mice (GEM) engineered to express oncogenes, or in which tumor 
suppressors have been disrupted, and spontaneously develop tumors, has revolutionized preclinical 
cancer research. Despite still having a few limitations, these mice are a realistic model that can predict 
the effectiveness of anti-cancer vaccines as the relationships between the incipient tumor, the immune 
system, and the surrounding tissues are preserved, while carcinogenesis progression can mimic what is 
observed in humans, including metastases development [32]. 
Results from several preclinical anti-cancer vaccination experiments in various GEM models have 
clearly shown that the elicited immune response and the efficacy of anti-tumor protection against 
autochthonous tumors becomes progressively lower as vaccination is started at later stages of 
carcinogenesis [13,14,27,35,36]. 
An example is provided by experiments in BALB-neuT mice. These mice are transgenic for the 
mutated form of the rat ortholog of the human epidermal growth factor receptor 2 (Her2) oncogene under 
the transcriptional control of the mouse mammary tumor virus promoter and develop mammary 
carcinomas with well-defined progression, which resembles that of human breast tumors in many  
aspects [37–39]. When BALB-neuT mice are vaccinated against Her2, using either cell- [40–43] or  
gene-based vaccines [27,30,35,44–48], the intensity and effectiveness of the induced immune response 
are inversely proportional to the stage of carcinogenesis progression at which vaccination is started. 
Mice bearing precancerous lesions were successfully protected with anti-Her2 vaccination alone. 
However, significant protection against microscopic neoplastic lesions was only achieved when anti-Her2 
vaccination was associated with protocols that contrast tumor-induced immune suppression, such as T 
regulatory cell depletion [13,49], or when vaccination was directed against the tumor vasculature, as in 
vaccination against angiomotin, which is one of the angiostatin receptors expressed by endothelial cells 
in BALB-neuT tumors [50]. These data thus demonstrate that cancer prevention is very much an 
obtainable goal [51,52].  
Down-modulation of major histocompatibility complex expression in murine [53] and human [54] 
tumors frequently hampers cytotoxic T cell (CTL) recognition. Mechanistic studies in Her2 transgenic 
mice revealed a strong contribution of helper T cell cytokines and anti-Her2 antibodies to cancer 
immunoprevention [35,40,42,46–48,55–57]. The different mechanisms at work in cancer prevention and 
therapy are reminiscent of viral immunity, in which infection is resolved by CTL, whereas prevention 
from re-infection is dependent on antibodies [14]. This parallelism with viral immunity [58] is further 
confirmed by the observation that transfer of anti-Her2 antibodies from immunized mothers to their 
cancer-prone BALB-neuT offspring delays mammary cancer progression [59]. 
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2.2. Companion Animals  
Another important lesson on the potentialities, and limits, of cancer vaccines can be found in their 
application in companion animals that bear naturally occurring tumors. Over the last decade, it has been 
recognized that naturally occurring tumors in cats and dogs mirror those in humans and are thus a 
powerful translational tool [60]. Effective vaccines against feline leukemia virus have been developed 
and are currently used in cats, but they can be associated with the development of vaccine-associated 
sarcomas at the site of injection that require aggressive surgery and, often, chemotherapy [61]. Therefore, 
testing of anti-cancer vaccines for translational purposes in cats must be done with caution. By contrast, 
this type of side effect is not seen in dogs that consequently have been more extensively used as a 
translational model for the development of anti-cancer vaccines. Results from a pioneering trial of anti-
tyrosinase vaccination in dogs affected by malignant melanoma [62] support the idea that only patients 
with local tumor control and no evidence of metastasis before vaccination can benefit from 
immunotherapy. This idea has been corroborated by the following studies [63,64] that were carried out 
using a vaccine that was approved by the United State Department of Agriculture in 2009 and is now 
commercialized as Oncept (Merial). Significant lengthening of overall survival in dogs with locally 
controlled stage II-III oral malignant melanoma that expresses chondroitin sulphate proteoglycan 
(CSPG) 4 has recently been achieved using an anti-CSPG4 DNA vaccine [65], further demonstrating 
that immunotherapy is effective against minimal residual disease. 
3. Human Cancer Immunoprevention  
The data from “classic” mouse preclinical models, together with those from comparative oncology 
models, clearly show that only animals bearing precancerous lesions, incipient tumors, and those that 
are at risk of developing recurrences and metastases after primary tumor removal are protected, meaning 
that anti-cancer vaccines are effective only when used in prophylactic settings, i.e., primary, secondary 
and tertiary prevention, as in the original concept of vaccination. If we transfer this concept to the human 
setting, it becomes clear that the application of immunotherapy regimens to the treatment of patients 
with advanced cancer is suboptimal. However, anti-cancer vaccines show significant potential if used to 
prevent tumor growth in healthy patients at a “high-risk” of developing a cancer—i.e., people with 
occupational exposure to carcinogens [66], or hereditary mutations in breast cancer (BRCA) genes [67], 
or in p53 [68], etc.—and when treating recurrence and metastasis in cancer patients with minimal 
residual disease. 
In this context, it must also be considered that cancer prevention is intended for healthy individuals, 
therefore, the lack of toxic side effects is as important as efficacy, whereas in cancer therapy, some 
degree of toxicity is acceptable. A case in point is the toxicity of cancer vaccines and adjuvants; 
therapeutic vaccines and adjuvants can cause local and systemic toxicities that would be forbidden in 
prophylactic vaccines. Vaccines currently used for primary cancer prevention, such as those against 
HBV and HPV, only cause low-grade toxicities. The same considerations apply to some of the vaccines 
and adjuvants that we will discuss in the following sections. Promising approaches tested in mice and in 
therapeutic clinical trials, such as immune checkpoint inhibitors, will not find application in human 
cancer prevention unless their toxicity is greatly reduced. 
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3.1. Primary Immunoprevention: A Futuristic Option for Non-Infection Associated Tumors?  
The potential of primary prevention in non-infection-associated tumors was already at the top of the 
tumor immunology top ten list in 2008 [52], however, for obvious reasons, its application is still 
confined to preclinical experiments. Nevertheless, this idea has recently paved the way for the 
foundation of the Artemis Project, whose (perhaps overoptimistic) goal [69] is to stop people dying of 
breast cancer by 2020 (http://www.breastcancerdeadline2020.org). This project, supported by the US 
National Breast Cancer Coalition, is based on the identification of breast cancer-specific neoantigens 
that are expressed in the early phases of carcinogenesis and against which prophylactic vaccines of 
various types can be generated.  
3.2. Secondary Immunoprevention: A Future Option Whose Efficacy Is Being Tested Now  
On ClinicalTrials.gov there are more than 1600 cancer vaccine trials listed. Some of them are 
examples of secondary immunoprevention and are discussed here (Table 3). Recently, a pilot trial 
(ClinicalTrials.gov identifier: NCT00107211) has seen 38 patients with in situ Her2-expressing ductal 
carcinoma (DCIS) being vaccinated one month before lumpectomy with autologous DC that  
were pulsed with six HLA class II promiscuous-binding peptides from Her2 (DC1 vaccine) [70].  
Vaccination was well-tolerated and induced a strong and long-lasting T cell response against Her2 in all 
but two treated patients and was independent from estrogen receptor (ER) and Her2 magnitude of 
expression. Nevertheless, the kind of clinical response observed at the time of lumpectomy in patients 
with ER positive and ER negative tumors was different, with the former displaying loss of Her2 tumor 
expression and the latter complete tumor regression [70]. In the future, we will discover whether the 
induced immune response has an impact on the risk of developing breast cancer events.  
In another recently concluded trial (NCT00773097) of secondary immunoprevention, patients with a 
history of advanced adenomas of the colon, which are a precursor to colon cancer, were vaccinated with 
a mucin1 (MUC1) 100-mer peptide admixed with the toll like receptor (TLR) 3 agonist Hiltonol [71]. 
An anti-MUC1 IgG response and long-term memory were observed in about 50% of vaccinated patients, 
without significant adverse events. The lack of detectable immune response in the other 50% of patients 
was correlated with an expanded number of circulating myeloid-derived suppressor cells (MDSC) before 
vaccination [72]. The monitoring of cancer occurrence in vaccinated patients in the coming years will 
allow us to evaluate the prophylactic potential of this MUC1 peptide vaccine in preventing colorectal 
cancer. A new randomized, placebo-controlled phase II efficacy trial (NCT02134925) with the same 
vaccine is now recruiting patients with colon adenomas; results are expected by 2020 [73]. 
3.3. Tertiary Immunoprevention: The Present Option 
Aside from these few examples of secondary prevention, the vast majority of cancer vaccines that have 
emerged from successful preclinical testing have been translated into clinical trials of tertiary cancer 
prevention (adjuvant therapy); here we discuss some of the more promising vaccine trials (Table 3). 
  
Vaccines 2015, 3 475 
 
 
Table 3. Cancer vaccine trials cited in the text. 
ClinicalTrials.gov 
Identifier 
Type of vaccine Patients with: Status 
NCT00107211 
Autologous DC pulsed with HLA class II 
promiscuous-binding peptides from Her2 
(DC1 vaccine) 
Her2+ breast DCIS Completed 
NCT00773097 
MUC1 100-mer peptide with Poly-ICLC 
Advanced colorectal adenoma  Completed 
NCT02134925 Advanced colon polyps Recruiting 
NCT01431391 
Autologous DC pulsed with the fusion 
protein PA2024 (sipuleucel-T) 
Castration refractory metastatic 
Prostate cancer 
Completed 
NCT00639639 
Autologous DC pulsed with CMV  
pp65-LAMP mRNA 
Glioblastoma multiforme 
Active, not 
recruiting 
NCT00524277 
Her2-derived HLA class I peptide (GP2) 
with GM-CSF 
Her2+ breast cancer 
Active, not 
recruiting 
NCT00841399 
Her2-derived HLA class I peptide (E75) 
with GM-CSF 
Her2+ breast cancer 
Completed 
NCT00854789 Completed 
NCT01479244 
Active, not 
recruiting 
NCT01510288 
GM-CSF-transfected allogeneic prostate 
cancer cells 
Castration refractory metastatic 
Prostate cancer 
Terminated 
NCT01417000 
GM-CSF-transfected allogeneic 
pancreatic cancer cells and CRS-207 
Metastatic pancreatic 
Adenocarcinoma 
Active, not 
recruiting 
NCT02004262 Recruiting 
NCT02243371 Recruiting 
NCT00077532 gp100-derived HLA class I peptide Advanced melanoma Completed 
The odyssey of the first Food and Drug Administration (FDA)-approved therapeutic cancer vaccine, 
sipuleucel-T (Provenge), is quite an interesting example. This DC-based vaccine was approved for the 
treatment of asymptomatic or minimally symptomatic metastatic castration-refractory prostate cancer 
patients in 2010 [74]. To make sipuleucel-T, the patient’s mononuclear cells are sent to a production 
plan to be pulsed with a proprietary fusion protein (PA2024), which combines the antigen prostatic acid 
phosphatase with granulocyte macrophage colony stimulating factor (GM-CSF). Cells are then sent back 
to the originating center for re-infusion into the patient. The first problem with this vaccine is the cost, 
too expensive to justify its use by National Health Service [75]. Secondly, the therapeutic benefit in term 
of survival, about four months versus placebo, was modest in this trial. Furthermore, it was argued that 
the benefit “could be the result of a flaw in the trial design or from the chance imbalance of unmeasured 
prognostic variables” [76–79]. Dendreon, the company making Provenge, had to file for Chapter 11 and 
the vaccine has recently been acquired by Valeant Pharmaceuticals [75]. Immediately after, the results 
of the interim assessments of cellular and humoral responses through 24 months from the STAND 
randomized, phase II trial (NCT01431391) were announced [80], showing that Provenge is effective in 
inducing a robust immune response in men with biochemically recurrent prostate cancer. However, data 
on the therapeutic efficacy are not yet available, making the sipuleucel-T odyssey an ongoing story.  
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Indeed, it is widely recognized that several factors contribute to limiting the efficacy of sipuleucel-T 
and the other DC-based vaccines [81]. The reduced ability of the cells in the vaccine to reach the lymph 
nodes is among these limiting factors. Pre-conditioning of the vaccine injection site with the 
tetanus/diphtheria (Td) toxoid has been shown to be effective in enhancing vaccine DC lymph node 
homing and their ability to stimulate tumor-antigen specific T cell responses in mice [82]. Thanks to 
these results, Mitchell and colleagues have recently conducted a randomized and blinded clinical trial 
(NCT00639639) for the treatment of patients affected by glioblastoma multiforme [82]. In this study,  
12 patients that were receiving chemotherapy after tumor removal were vaccinated monthly with autologous 
dendritic cells pulsed with Cytomegalovirus (CMV) phosphoprotein 65 (pp65)-lysosomal-associated 
membrane protein (LAMP) mRNA, which is expressed in 90% of glioblastoma tissues, but not in normal 
brain tissue. Patients received either autologous non-pulsed DC (as control) or Td at the vaccine injection 
site prior to vaccination, with or without autologous lymphocyte transfer. Despite the aggressiveness of 
glioblastoma multiforme, patients receiving Td before pp65 pulsed DC displayed a significant  
increase in both progression-free and overall survival [82] as compared to patients whose vaccine site 
pre-conditioning included only the injection of autologous DC. The clinical benefit observed in this 
small but very promising clinical trial was associated with a significantly higher accumulation of injected 
DC at the vaccine site draining lymph nodes and a higher, longer-lasting specific pp65 T cell response.  
Data from another promising trial of tertiary immunoprevention were presented at the American 
Society of Clinical Oncology Breast Cancer Symposium in September 2014. In this randomized phase 
II trial (NCT00524277), breast cancer patients (any Her2 and ER expression) with no evidence of disease 
after completing standard treatments, including trastuzumab (Herceptin), either received the Her2-derived 
HLA class I peptide, called GP2, in combination with GM-CSF, or GM-CSF alone [83]. The vaccine 
significantly reduced the risk of recurrence and, as expected, patients with Her2+ tumors benefited most 
from the vaccination [83]. However, it is worth noting that no definitive conclusion can be drawn from 
this trial as the number of Her2+ patients was relatively small (48 and 50 in the vaccinated and control 
group, respectively) and the balancing of the two arms of the trial, in terms of tumor size, hormone and 
nodal status, should have been more carefully evaluated. 
An even more promising vaccine against Her2, which has been tested in phase II clinical trials 
(NCT00841399, NCT00854789), is Neuvax. This is an HLA-A*0201-restricted immunogenic Her2 
nonapeptide which is intradermally injected in combination with GM-CSF [84]. Patients with breast 
tumors expressing any degree of Her2 enrolled for the trial received standard of care therapy and were 
confirmed to be disease-free prior to enrollment. The vaccine was administered once a month for six 
months and was followed by booster shots once every six months thereafter. Disease-free survival (DFS) 
at five years was 89.7% in the vaccinated group versus 80.2% in the control group. Unexpectedly, 
vaccinated patients with Her2 low-expressing tumors were those that displayed the better DFS  
numbers [84,85]. This paradoxical result remains still unexplained. A randomized, multicenter phase III 
study (NCT01479244) for patients with early-stage, lymph-node-positive breast tumors that express low 
to intermediate levels of Her2 started in 2012 and aimed to confirm efficacy and safety in a larger 
population. Even if results are not yet available, nevertheless, this ongoing trial is currently the most 
advanced step in the development of a vaccine strategy to prevent breast cancer recurrence.  
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As it capitalizes on this wealth of information, cancer immunoprevention is now revolutionizing the 
way we treat cancer and offers unprecedented opportunities for improving the management of cancer 
patients on a rational basis. 
4. Checkpoint Blockade as a Biological Adjuvant for Cancer Immunoprevention:  
Work in Progress 
Established, growing tumors are strongly immune-suppressive and give the organism little chance to 
induce effective and long-lasting immunity against self-tolerated molecules such as tumor antigens. 
Finding appropriate strategies for counteracting tumor-induced immune suppression would allow for the 
successful application of cancer vaccines in therapeutic settings. 
Several inhibitory pathways that contribute to tumor-induced immunosuppression (cytokines, 
suppressive cell population, amino acid-catabolizing enzymes, and ligation of inhibitory receptors on 
activated T cells) have been identified and their blockade in cancer patients is under investigation. The 
two most promising strategies used so far are the administration of low doses of chemotherapeutics at 
short intervals (metronomic chemotherapy) [86] and the administration of monoclonal antibodies 
(mAbs) directed against inhibitory molecules of the immune system [87].  
Besides exerting antiangiogenic activity, metronomic chemotherapy stimulates anti-cancer immune 
responses by selectively eliminating T regulatory cells and MDSC [88]. Thus, it is a good candidate for 
use together with cancer vaccines for the therapy of various tumor types [89]. 
Several mAbs directed against inhibitory receptors have been generated and tested in preclinical 
models. These include mAbs against cytotoxic T lymphocyte-associated protein 4 (CTLA-4) [90,91]; 
programmed cell death 1 (PD-1) [92,93] and its ligand (PD-L1 or B7-H1) [92,94]; members of the killer 
cell immunoglobulin-like receptor (KIR) family [95]; tumor necrosis factor receptor superfamily member 
4 (TNFRSF4 or OX40) [96–98]; TNFRSF9 (CD137 or 4-1BB) [99,100]; TNFRSF18 (GITR) [101]; and 
the transforming growth factor β1 (TGFβ1) [102]. Most of these mAbs have also been tested in patients 
bearing differing forms of solid cancer. However, only anti-CTLA-4 and anti-PD-1 mAbs have been 
FDA-approved for use in the clinic [22]. They are the fully human antagonistic anti-CTLA-4 mAb, 
ipilimumab (Yervoy), the fully human (nivolumab; Opdivo) and the humanized (pembrolizumab; 
Keytruda) programmed death receptor-1 (PD-1)-blocking mAbs. 
CTLA-4 and PD-1 inhibitory checkpoint pathways act in temporally and spatially distinct ways 
in regulating T cell response (Figure 2). CTLA-4 is mainly involved in the priming phase in 
secondary lymphoid organs, while PD-1 dampens the effector functions of already activated T cells 
in the periphery [103]. 
Ipilimumab was the first immunotherapeutic drug which was able to induce long-term durable 
responses and improve overall survival in patients with metastatic melanoma [104–106]. As such, it was 
licensed by the FDA for use in patients with unresectable advanced metastatic melanoma in 2011 [107]. 
In 2014, the FDA licensed pembrolizumab [108] for the treatment of metastatic melanoma patients who 
do not respond to ipilimumab [109] or BRAF inhibitors [110]. Pembrolizumab is now being tested in 
phase II/III trials in non-small-cell lung cancer (NSCLC) patients with oligometastatic disease [111] and 
as a monotherapy and combination therapy in 30 different cancer subtypes [112]. Nivolumab was  
FDA-approved for the treatment of advanced melanoma in December 2014, following the publication 
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of results from a completed Phase III clinical trial demonstrating a significant improvement in 
progression-free and overall survival in patients with melanoma without the BRAF mutation [113].  
On March 4th, 2015, Nivolumab also received FDA approval for the treatment of NSCLC patients as a 
recent phase III trial (NCT01642004) was stopped ahead of schedule because it had already met its 
endpoint: superior overall survival in nivolumab-treated patients compared to the standard therapy control 
arm [114]. The checkpoint inhibitors nivolumab and ipilimumab had demonstrated a synergic effect when 
given in combination to patients with advanced melanoma [115], and gave a two-year survival rate of 
about 80% [116]. The combination also resulted in increased side effects as compared to therapy with 
either agent alone; however, most side effects were still manageable and reversible, and similar to those 
experienced with ipilimumab alone [116]. Other ongoing clinical trials in patients with other tumor types 
are also providing encouraging results [117]. 
 
Figure 2. Schematic representation of the basic principles of checkpoint inhibition. The 
potential roles of the inhibition of CTLA-4 during the priming of T cells in secondary 
lymphoid organs and of PD-1 and its ligands (PD-L) during the effector phase in the tumor 
microenvironment are shown. 
The effective elimination of a tumor requires coordinated immune mechanisms involving both the 
activation of immune effector cells and the removal of suppressor mechanisms. Therefore, there is a 
strong rationale for combining anti-cancer vaccines with either checkpoint inhibitors or metronomic 
chemotherapy [118]. However, only a few combination immunotherapy trials have been reported to  
date [119–121], some of which are listed in Table 3. Nevertheless, none of them incorporate single agent 
control arms, therefore conclusions on the possible additive/synergistic effects of the combination 
therapies are impossible to make.  
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A GM-CSF gene-transfected allogeneic tumor cell vaccine (GVAX), which is based on prostate 
cancer cells given in combination with ipilimumab, has recently been shown (NCT01510288) to be safe 
and tolerable in patients affected by metastatic castration-resistant prostate cancer that had not been 
previously treated with chemotherapy [119]. 
In a multicenter randomized phase II trial (NCT01417000), patients with metastatic pancreatic 
adenocarcinoma were treated with a pancreatic GVAX in combination with low doses of cyclophosphamide 
and a recombinant live-attenuated double-deleted Listeria monocytogenes secreting pancreatic 
adenocarcinoma tumor antigen, mesothelin (CRS-207) [122]. Extended overall survival as well as the 
induction of higher numbers of mesothelin-specific CD8 T cells were both observed in patients treated 
with the combination therapy as compared to those only treated with GVAX and cyclophosphamide 
[120]. Based on these results, a randomized, controlled, and three-arm trial will evaluate the safety, 
immune response, and efficacy of the combination immunotherapy of pancreatic GVAX, low-dose 
cyclophosphamide, and CRS-207 as compared to chemotherapy or CRS-207 alone (NCT02004262). In 
addition, since the FDA has designated CRS-207 and pancreatic GVAX combination therapy a 
breakthrough therapy, it will now also be evaluated in combination with the checkpoint inhibitor 
nivolumab in patients with metastatic pancreatic cancer (NCT02243371). Results are expected in 
January 2019. 
A phase III clinical trial combining a gp-100 peptide vaccine with ipilimumab was performed in 
patients affected by advanced metastatic melanoma [121]. Ipilimumab, whether used with or without the 
vaccine, improved overall survival as compared to gp100 alone. Severe adverse events were observed, 
but most were reversible with appropriate treatment. 
These initial results allow space for an optimistic view of the future. We have promising tools with 
which to fight several types of cancers, including melanoma, glioblastoma, NSCLC, breast, prostate, 
pancreatic, and colon cancer. However, they now need to be studied in depth for us to find the best 
combinations for use in cancer patients at various stages of their disease. 
5. Target Antigens for Cancer Immunoprevention: Drivers or Passengers? 
The analysis of tumor genomes is currently creating new opportunities in many sectors of oncology, 
including the study of tumor antigens. Molecular studies have discovered most tumor antigens that are 
commonly expressed by human tumors over the last century, but have barely scratched the surface when 
it comes to individual antigens, i.e., those distinctive tumor antigens that derive from random mutations 
in each patient and that are potentially unique to his/her tumor. 
Tumor immunologists are currently quite similar to the theoretical physicists who predicted the 
existence of a class of particles: we knew that individual tumor antigens existed, but now, thanks to DNA 
sequencing, we are able to recognize them experimentally and to devise specific therapeutic strategies. 
Presently, “therapeutic” is the operative word as the application of individual neoantigens to cancer 
immunoprevention is not yet a reality. However, sequencing could be translated into new approaches to 
secondary and tertiary immunoprevention in which individual tumor antigens, discovered in preneoplastic, 
early neoplastic, or primary lesions, can then be targeted with specific vaccines [123,124]. 
One of the fundamental issues here is the relationship between neoantigens and neoplastic transformation. 
Mutations in cancer cells are commonly divided into “drivers” and “passengers”. The former encompasses 
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all mutations in cancer genes that cause and sustain tumorigenicity. However, the mutagenic processes 
that cause driver mutations invariably produce a large number of random passenger mutations, which do 
not contribute to the neoplastic phenotype [125]. 
From an immunological point of view, both driver and passenger mutations are equally interesting, 
as long as they give rise to recognizable tumor antigens. Great interest currently surrounds passenger 
tumor antigens because patients that are responsive to non-antigen specific immunotherapies, or to 
antigen-specific therapies against previously unknown specificities, were recently shown to express and 
recognize this type of neoantigen [126,127]. 
Returning to cancer immunoprevention, we must consider that passenger tumor antigens can be 
intrinsically less persistent than antigens that derive from mutations in driver cancer genes [128], because 
antigens that are unrelated to the growth and spread of cancer cells will easily be lost, or down-modulated, 
in the presence of an immune response. We coined the term “oncoantigens” to distinguish persistent 
tumor antigens that are directly or indirectly related to the survival, growth, and spread of tumor cells [14]. 
Thus, a number of different scenarios can be envisaged where the choice of antigens is matched with 
the type of cancer immunoprevention. 
For pure primary cancer immunoprevention in healthy individuals, the governing rule is primum non 
nocere, hence, vaccines will be necessarily directed against oncofetal and “retired” antigens, i.e., 
molecules that are no longer expressed in the individual at risk, but are likely to be expressed in tumors [129]. 
If such molecules are not oncoantigens, it remains to be determined whether nascent tumors can easily 
give rise to antigen-negative variants or not. For groups of high-risk individuals (e.g., asbestos exposure, 
or BRCA1/2 carriers), the risk factor itself may be predictive of a specific constellation of tumor 
antigens, while vaccine side effects can be tolerated as the risk of carcinogenesis approaches certainty. 
In secondary immunoprevention, an in-depth “omic” analysis of existing preneoplastic or early 
neoplastic lesions could reveal the presence of individual antigens, in addition to those that are 
commonly expressed [51]. The need for long-term immunity against the continuous risk of neoplastic 
transformation will orient the formulation of vaccines against persistent tumor antigens.  
For tertiary cancer immunoprevention, the bulk of molecular information will come from the analysis 
of the primary tumor. Vaccines against antigens that are encoded by passenger mutations will find their 
best application in adjuvant immunotherapy because the immune-mediated attack on micrometastatic 
foci may be sufficiently rapid and destructive to prevent the generation of antigen-loss clones [130]. 
6. Conclusions 
Vaccines against HBV and HPV effectively prevent hepatocellular and cervical carcinomas. 
Preclinical evidence shows that vaccines can also prevent tumors unrelated to infectios agents, which 
are the majority of human tumors. Early clinical trials are now translating immunoprevention to humans 
at risk of breast and colorectal cancer. The definition of optimal target antigens and the inhibition of 
immune checkpoints can enhance the efficacy of preventive cancer vaccines and pave the way to a 
broader application of cancer immunoprevention. 
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